The patient became febrile a few days into his hospital course. Empiric vancomycin and ceftriaxone were initiated for culturenegative endocarditis, but fevers persisted. On day 9 of his hospital stay he underwent surgical extraction of the pacemaker and leads. Although the operative mortality of this procedure is known to be high, it was decided the benefit outweighed the risk of embolization with medical management alone. Intraoperatively, invasion by the vegetation of the right atrium, tricuspid valve, interatrial septum, and superior vena cava was noted, and these areas were debulked. There was no indication at that point for a pacemaker, therefore it was not reimplanted. Operative pathology revealed tissue invasion by branching fungal hyphae ( Figure 2 ) and several operative cultures grew pure cultures of A. fumigatus. Antibiotics were changed to intravenous voriconazole. On hospital day 17 he was discharged home on indefinite suppression with oral voriconazole. The galactomannan antigen assay (Bio-Rad Laboratories, Hercules, California), sent while on antifungal therapy, was positive (index = 0.94; positive reference cut-off: index !0.5). The 1!3-b-D-glucan assay was not performed. At 6-month follow-up he continued to do well, had gained weight, and clinically had had no apparent recurrence of Aspergillus disease or progression of MDS. It is anticipated that he will remain on voriconazole indefinitely.
Prevalence
Aspergillus species cause approximately 20-30% of all fungal endocarditis cases. 1, 2 The proportion of fungal endocarditis caused by Aspergillus was similar in 1965-1971 (18/64 or 28%) and 1988-1995 (14/58 or 24%), suggesting that the prevalence of Aspergillus did not change significantly between 1965 and 1995. 1 The ratio of Aspergillus to Candida (1:2) has also remained constant over the last three decades. 1 A recent review of fungal endocarditis between 1995 and 2000 yielded 152 cases of fungal endocarditis, 28 (18%) of which were caused by Aspergillus. 2 The majority of cases were caused by A. fumigatus (54%), followed by Aspergillus terreus (18%), Aspergillus niger (7%), and Aspergillus flavus (7%). Aspergillus species have also been associated with CDRIE. A retrospective review of all infected cardiac devices at the Mayo Clinic between 1991 and 2003 found 44 patients who met the definition of CDRIE; 75% of these cases of CDRIE were associated with pacemakers and 25% with automated implantable cardiac defibrillators. Fungal infections were demonstrated in only three of the 44 patients with CDRIE, two of which were Aspergillus (5% of all CDRIE cases). 3 A similar retrospective study of infections among 33 patients with pacemaker endocarditis was performed in Paris, France between 1988 and 1996. 4 In this study, two of 33 patients had fungal endocarditis, one case of which was caused by Aspergillus (3% of CDRIE cases).
Risk factors
A review of the literature indicates that most patients with Aspergillus endocarditis are male and possess a predisposing condition. 2, 5, 6 Pierrotti and Baddour assessed risk factors for moldrelated endocarditis among 39 patients, the majority of which was caused by Aspergillus, and found an association with underlying cardiac abnormalities (41%), prosthetic valves (39%), malignancy (18%), solid-organ transplants (18%), and bone marrow transplants (18%). 2 Woods et al. reported steroid treatment (55%), prolonged antibiotic exposure (31%), hematological malignancy (28%), and chemotherapy and cytotoxic therapy (28%) as the most common predisposing factors for Aspergillus endocarditis in 29 patients. 5 Among children, congenital heart disease appears to be the most common risk factor, accounting for 67% of cases in one pediatric series of 15 patients. 6 In our patient, the major predisposing conditions were the evolving MDS and previous pacemaker. He had not received recent immunosuppressive therapy and was not known to have congenital heart disease.
Literature review of Aspergillus endocarditis
We conducted a Medline search for cases of Aspergillus endocarditis using search terms 'Aspergillus' and 'endocarditis' [ ( F i g u r e _ 2 ) T D $ F I G ] for January 1950 through July 2010, yielding 53 case reports, which are summarized in Table 1 . Table 1 describes the clinical presentations, associated co-morbidities, diagnostics, treatments, complications, and outcomes of these cases. Over half of the 53 cases reviewed had fever (57%) or evidence of embolic disease (53%) at initial presentation (Table 1) . Vegetations were often large and involved the mitral (26/53 or 49%) or aortic valves (24/53 or 45%), and less frequently, the tricuspid valve (9/53 or 17%), cardiac device leads (5/53 or 9%), or pulmonic valve (1/53 or 2%). Multi-valve involvement was seen in 21% (11/53) of cases. Complications were common and frequently involved embolization (40/53 or 75%) to the pulmonary, ophthalmic, cerebral, iliac, coronary, hepatic, splenic, renal, brachial, and/ or mesenteric arteries.
Cyanotic spells are an uncommon initial manifestation of Aspergillus endocarditis, and may represent ventilation-perfusion mismatch or shunting due to recurrent septic pulmonary emboli.
Diagnosis
The diagnosis of Aspergillus endocarditis requires a high index of suspicion. Diagnosis was established postmortem in 11/53 (21%) cases by our review. Blood cultures are almost always negative (51/ 53 or 96%). Fungal vegetations are frequently large. The vegetation in our patient was large (3.5 cm Â 2 cm) and demonstrated by TTE without difficulty.
The galactomannan antigen assay can be a useful adjunctive test to establish the diagnosis of invasive aspergillosis, but has not been studied in the setting of endocarditis. It is more sensitive for detecting invasive disease due to non-fumigatus Aspergillus than. A. fumigatus (49% vs. 13%). 7 False-positive results can occur with fungal infections (i.e., histoplasmosis, blastomycosis, cryptococcosis, and penicilliosis), as well as concomitant antibiotic therapy with piperacillin-tazobactam and amoxicillinclavulanate. [8] [9] [10] [11] [12] [13] Ultimately, the diagnosis requires histological and tissue culture confirmation to differentiate Aspergillus from other molds and to determine the species. Pathology typically demonstrates acute angle branching and septate hyphae on Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS) stains.
Treatment
The treatment of Aspergillus endocarditis is largely guided by evidence from the treatment of other forms of invasive Aspergillus infection. Successful treatment of endocarditis requires the combination of antifungal therapy and surgical debridement. The recommended antifungal therapy for most invasive Aspergillus infections, including Aspergillus endocarditis, is voriconazole. 14 The superiority of voriconazole to amphotericin B deoxycholate was demonstrated in a large, randomized controlled trial of invasive Aspergillus infections, the majority of which involved the lungs and sinuses (92%). Compared to amphotericin B, voriconazole was associated with improved survival, and less nephrotoxicity, electrolyte abnormalities, and infusion-related events. 15 Intravenous liposomal amphotericin formulations provide a second treatment option, with equal efficacy and less nephrotoxicity than amphotericin B in the treatment of invasive Aspergillus infections. 16 Finally, surgical debridement is imperative for the survival of almost all cases of Aspergillus endocarditis. 
Prognosis
The prognosis is poor, with only 17 of 53 reported cases (32%) surviving the acute episode of Aspergillus endocarditis. This may be in part because of the immunocompromised status of the hosts, delay in diagnosis, and rapidity of embolization. Mortality approaches 100% among those who receive medical therapy alone.
Summary
Aspergillus endocarditis, specifically cardiac device-related infection, is very rare. It should be suspected in persons with underlying hematological malignancies, recent cardiothoracic surgery, intravenous drug use, and immunosuppression with culture-negative endocarditis and/or systemic or pulmonary emboli. Diagnosis ultimately requires confirmation by tissue histology and culture. The optimal treatment approach requires aggressive surgical debridement combined with antifungal treatment, usually requiring indefinite therapy with voriconazole.
